Jaar: 2013
-
Large scale discovery of minor histocompatibility antigens valuable for immunotherapy of hematological tumors.
In this project we aimed to search for clinical relevant minor histocompatibility antigens (MiHAs) by combining HLA-ligandome analyses with RNA expression databases. T cells recognizing these clinically relevant MiHAs could potentially induce a leukemia specific immune reaction after allogeneic stem…
-
Non-regular grant – Molecular and Cellular Haematology Research Program
Overall aim and key objectives of the program Covering the complete spectrum of blood and blood transfusion research, Sanquin aims to perform original science on not only basic and clinical but also applied topics. As a consequence our research departments…
-
Role of platelet Toll-like receptor signaling in hemostasis and inflammation.
The present project has addressed the role of platelets in sepsis. Sepsis is a dysregulated host response to an infection. During infection (with e.g. bacteria), the immune system responds to combat the infection. When this response is dysregulated, the activated…
-
SMIM1, the VEL-antigen, a novel regulator of erythropoiesis.
In this project we investigated the function of SMIM1, the recently characterized protein carrying the VEL blood group system. Anti-Vel antibodies can cause serious transfusion reactions. In previous research we obtained indications that SMIM1 might be a novel regulator of…
-
Tracing human dendritic cell development from a common precursor of dendritic cells and osteoclasts.
Dendritic cells (DCs), macrophages and osteoclasts (OCs) are very important cell types that are relevant in many diseases, including cancer and autoimmune diseases, such as rheumatoid arthritis. These cell types are closely related and stem from hematopoietic progenitors. However, the…
-
Ubiquitylation and acetylation in leukocyte-vessel wall interactions and inflammation.
An important aspect of our blood vessels is their permeability. This permeability allows for efficient exchange of nutrients and waste between blood and tissues as well as for extravasation of leukocytes to sites of acute or chronic inflammation. Our blood…
-
What keeps tumor infiltrating T cells from being effector cells?
CD8+ T cells are potent effector cells that recognize and kill infected cells and tumor cells. They do so by producing copious amounts of effector molecules, such as cytokines. In the past years, T cells have been used as a…
-
What keeps tumor infiltrating T cells from being effector cells?
CD8+ T cells are potent effector cells that recognize and kill infected cells and tumor cells. They do so by producing copious amounts of effector molecules, such as cytokines. In the past years, T cells have been used as a…